Testing a new immunotherapy for myeloma that returns after CAR T-cell therapy
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new medication (linvoseltamab) for people with multiple myeloma that has returned after CAR T-cell therapy. The goal is to see if this new treatment can help control the cancer when the previous treatment stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have had BCMA CAR T-cell therapy for your myeloma, and it was your last treatment at least 6 months ago (or a bit sooner if you meet special conditions).
- Your myeloma must have come back after that CAR T-cell therapy.
- You must have signs of active myeloma that can be checked by blood tests or imaging.
- Your liver and kidneys must be working well enough, as determined by blood tests.
- You cannot have had any other BCMA-targeting treatment besides CAR T-cell therapy, and you must not have certain infections or heart or brain conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
This trial tests an immunotherapy drug combination for people newly diagnosed with multiple myeloma who have had some response to initial treatment but still have signs of disease. The goal is to see if this approach can help eliminate remaining cancer cells and potentially improve outcomes.
This trial tests linvoseltamab, an experimental antibody medicine, in adults whose multiple myeloma has come back or does not respond to treatment. It may help some people by targeting myeloma cells after multiple prior therapies have failed.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
This trial compares a new drug called linvoseltamab to standard treatments for multiple myeloma. It is for people who cannot have a stem cell transplant and have not had extensive prior therapy.
This trial tests adding a new drug, linvoseltamab, to the standard maintenance therapy lenalidomide for people with newly diagnosed multiple myeloma. The goal is to see if it can deepen responses or turn a relapse back to a negative minimal residual disease (MRD) state, where no cancer cells are detectable.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.